[go: up one dir, main page]

AR074470A1 - Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes - Google Patents

Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes

Info

Publication number
AR074470A1
AR074470A1 ARP090104672A ARP090104672A AR074470A1 AR 074470 A1 AR074470 A1 AR 074470A1 AR P090104672 A ARP090104672 A AR P090104672A AR P090104672 A ARP090104672 A AR P090104672A AR 074470 A1 AR074470 A1 AR 074470A1
Authority
AR
Argentina
Prior art keywords
diabetes
compound
prepare
treatment
pharmaceutical composition
Prior art date
Application number
ARP090104672A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR074470A1 publication Critical patent/AR074470A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Composición farmacéutica que lo comprende. Uso de dicho compuesto para preparar un medicamento útil para el tratamiento de diabetes, como ser diabetes tipo II. Reivindicación 1: Un compuesto de amida del ácido ciclopropanocarboxílico caracterizado porque es de la fórmula (1) o una sal farmacéuticamente aceptable del mismo. Reivindicación 2: El compuesto de conformidad con la reivindicación 1, caracterizado porque tiene la fórmula (2)
ARP090104672A 2008-12-19 2009-12-03 Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes AR074470A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19

Publications (1)

Publication Number Publication Date
AR074470A1 true AR074470A1 (es) 2011-01-19

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104672A AR074470A1 (es) 2008-12-19 2009-12-03 Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes

Country Status (34)

Country Link
US (1) US8063079B2 (es)
EP (1) EP2379517B1 (es)
JP (1) JP5497064B2 (es)
KR (1) KR101290437B1 (es)
CN (1) CN102256952B (es)
AR (1) AR074470A1 (es)
AU (1) AU2009335931B2 (es)
BR (1) BRPI0923183B1 (es)
CA (1) CA2746746C (es)
CO (1) CO6382120A2 (es)
CR (1) CR20110342A (es)
DK (1) DK2379517T3 (es)
DO (1) DOP2011000197A (es)
EA (1) EA019055B1 (es)
EC (1) ECSP11011150A (es)
ES (1) ES2435242T3 (es)
HR (1) HRP20130983T1 (es)
IL (1) IL213210A (es)
JO (1) JO2979B1 (es)
MA (1) MA32902B1 (es)
MX (1) MX2011006434A (es)
MY (1) MY180567A (es)
NZ (1) NZ592930A (es)
PA (1) PA8851901A1 (es)
PE (1) PE20120339A1 (es)
PL (1) PL2379517T3 (es)
PT (1) PT2379517E (es)
SG (1) SG172256A1 (es)
SI (1) SI2379517T1 (es)
TN (1) TN2011000294A1 (es)
TW (1) TWI395748B (es)
UA (1) UA104742C2 (es)
WO (1) WO2010080333A1 (es)
ZA (1) ZA201103944B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936608B1 (en) 2010-03-31 2025-05-07 The Scripps Research Institute Reprogramming cells
CN110302394A (zh) 2013-11-22 2019-10-08 国立大学法人东京大学 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6388071B2 (en) 2000-05-03 2002-05-14 Hoffmann-La Roche Inc. Alkynyl phenyl heteroaromatic glucokinase activators
CA2407763C (en) 2000-05-08 2007-04-24 Fred Thomas Bizzarro Para-amine substituted phenylamide glucokinase activators
MXPA02010796A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Fenilacetamidas sustituidas y sus usos como activadores de glucocinasa.
US7132425B2 (en) * 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003297291A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
KR20050105488A (ko) * 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
MXPA06012008A (es) 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
KR20080105180A (ko) 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
KR101066882B1 (ko) * 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. 헤테로방향족 글루코키나제 활성화제
EP1907004A2 (en) 2005-07-01 2008-04-09 Novartis AG Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
US7514439B2 (en) 2005-07-11 2009-04-07 Mitsubishi Tanabe Pharma Corporation Oxime derivative and preparations thereof
JP2009504621A (ja) * 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
JP2009514836A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
BRPI0618062A2 (pt) 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
MX2009000688A (es) * 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
JP5207981B2 (ja) * 2007-01-10 2013-06-12 田辺三菱製薬株式会社 ヒドラゾン誘導体
MX2010011778A (es) 2008-04-28 2010-11-30 Kyorin Seiyaku Kk Derivados de ciclopentil acrilamida.

Also Published As

Publication number Publication date
ES2435242T3 (es) 2013-12-17
BRPI0923183A2 (pt) 2016-02-16
HRP20130983T1 (hr) 2013-11-22
JP2012512874A (ja) 2012-06-07
MY180567A (en) 2020-12-02
CN102256952B (zh) 2013-12-11
BRPI0923183A8 (pt) 2017-09-12
EA019055B1 (ru) 2013-12-30
PL2379517T3 (pl) 2014-01-31
MA32902B1 (fr) 2011-12-01
CR20110342A (es) 2011-09-14
EA201170845A1 (ru) 2011-12-30
AU2009335931A1 (en) 2011-07-07
UA104742C2 (uk) 2014-03-11
PT2379517E (pt) 2013-11-21
DOP2011000197A (es) 2011-09-15
PE20120339A1 (es) 2012-04-16
CA2746746C (en) 2013-09-24
JP5497064B2 (ja) 2014-05-21
NZ592930A (en) 2013-01-25
SI2379517T1 (sl) 2013-10-30
PA8851901A1 (es) 2010-07-27
EP2379517A1 (en) 2011-10-26
KR101290437B1 (ko) 2013-07-29
US8063079B2 (en) 2011-11-22
IL213210A0 (en) 2011-07-31
IL213210A (en) 2015-03-31
SG172256A1 (en) 2011-07-28
AU2009335931B2 (en) 2012-05-31
US20100160395A1 (en) 2010-06-24
EP2379517B1 (en) 2013-08-28
BRPI0923183B1 (pt) 2019-03-19
DK2379517T3 (da) 2013-09-30
CO6382120A2 (es) 2012-02-15
WO2010080333A1 (en) 2010-07-15
MX2011006434A (es) 2011-07-19
ECSP11011150A (es) 2011-07-29
KR20110086751A (ko) 2011-07-29
CA2746746A1 (en) 2010-07-15
CN102256952A (zh) 2011-11-23
JO2979B1 (en) 2016-03-15
TN2011000294A1 (en) 2012-12-17
TWI395748B (zh) 2013-05-11
ZA201103944B (en) 2012-11-28
TW201029999A (en) 2010-08-16

Similar Documents

Publication Publication Date Title
BR112015005972A2 (pt) derivados do tipo amida de ácido benzoimidazol-carboxílico como moduladores do receptor apj
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
MX369259B (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
GT201200164A (es) "nuevos compuestos de espiropiperidina"
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
PE20120713A1 (es) Composiciones sublinguales de dexmedetomidina y metodos para su uso
CL2012002031A1 (es) Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
CL2010000935A1 (es) Compuestos derivados de niacina unida a un acido graso; composicion farmaceutica que los comprende; y su uso para tratar una enfermedad metabolica tal como hipertrigliceridemia, hipercolesterolemia, diabetes tipo 2 y retinopatia diabetica.
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
MX2020005738A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
PH12017500136A1 (en) Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
IN2012DN02502A (es)
BR112015004523A2 (pt) compostos de tetraciclina
NI201300007A (es) Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol.
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
WO2015009731A3 (en) Azacyclic constrained analogs of fty720

Legal Events

Date Code Title Description
FG Grant, registration